![ORCID 0000-0002-0768-245X](/images/orcid_16x16.gif)
![ORCID 0000-0002-6815-444X](/images/orcid_16x16.gif)
![ORCID 0000-0001-8380-9371](/images/orcid_16x16.gif)
![ORCID 0000-0001-8259-8090](/images/orcid_16x16.gif)
Dokumentenart: | Artikel | ||||
---|---|---|---|---|---|
Titel eines Journals oder einer Zeitschrift: | Progress in Cardiovascular Diseases | ||||
Verlag: | W B SAUNDERS CO-ELSEVIER INC | ||||
Ort der Veröffentlichung: | PHILADELPHIA | ||||
Band: | 73 | ||||
Seitenbereich: | S. 41-47 | ||||
Datum: | 2022 | ||||
Institutionen: | Medizin > Lehrstuhl für Neurologie | ||||
Identifikationsnummer: |
| ||||
Stichwörter / Keywords: | INTIMA-MEDIA THICKNESS; STROKE PREVENTION; DIABETES-MELLITUS; CARDIOVASCULAR EVENTS; AGGRESSIVE REDUCTION; METAANALYSIS; THERAPY; MORTALITY; EFFICACY; SAFETY; Carotid artery stenosis; Best medical treatment; Carotid endarterectomy; Carotid artery stenting; Statins; Proprotein convertase subtilisin; kexin type 9 (PCSK9) inhibitors | ||||
Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
Status: | Veröffentlicht | ||||
Begutachtet: | Ja, diese Version wurde begutachtet | ||||
An der Universität Regensburg entstanden: | Ja | ||||
Dokumenten-ID: | 57788 |
Zusammenfassung
International guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of ...
![plus plus](/style/images/plus.png)
Zusammenfassung
International guidelines strongly recommend statins alone or in combination with other lipid-lowering agents to lower low-density lipoprotein cholesterol (LDL-C) levels for patients with asymptomatic/symptomatic carotid stenosis (AsxCS/SCS). Lowering LDL-C levels is associated with significant reductions in transient ischemic attack, stroke, cardiovascular (CV) event and death rates. The aim of this multi-disciplinary overview is to summarize the benefits and risks associated with lowering LDL-C with statins or non-statin medications for Asx/SCS patients. The cerebrovascular and CV beneficial effects associated with statins, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and other non-statin lipid-lowering agents (e.g. fibrates, ezetimibe) are reviewed. The use of statins and PCSK9 inhibitors is associated with several beneficial effects for Asx/SCS patients, including carotid plaque stabilization and reduction of stroke rates. Ezetimibe and fibrates are associated with smaller reductions in stroke rates. The side-effects resulting from statin and PCSK9 inhibitor use are also highlighted. The benefits associated with lowering LDL-C with statins or non-statin lipid lowering agents (e.g. PCSK9 inhibi-tors) outweigh the risks and potential side-effects. Irrespective of their LDL-C levels, all Asx/SCS patients should receive high-dose statin treatment +/- ezetimibe or PCSK9 inhibitors for reduction not only of LDL-C levels, but also of stroke, cardiovascular mortality and coronary event rates.(c) 2022 Elsevier Inc. All rights reserved.
Metadaten zuletzt geändert: 29 Feb 2024 13:02